Igor-Wolfgang Blau

10.3k citations
197 papers · 7.9k · 3 hit papers · h-index 40

Impact in

  • Hematology top 0.1%
    • Multiple Myeloma Research and Treatments
    • Hematopoietic Stem Cell Transplantation
    • Acute Myeloid Leukemia Research
  • Virology top 0.5%
    • HIV Research and Treatment

Papers in

    • Multiple Myeloma Research and Treatments 75
    • Hematopoietic Stem Cell Transplantation 63
    • Acute Myeloid Leukemia Research 60
    • Cancer Treatment and Pharmacology 20
    • Peptidase Inhibition and Analysis 18

Igor-Wolfgang Blau

188 papers receiving 7.7k citations

Igor-Wolfgang Blau's Hit Papers

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial 2019 · 316 citations
3160+5+11Years since publication4008001.2k

Peers

Igor-Wolfgang Blau
Comparison fields: 5 of 124
  • Hematology 4.6k
  • Virology 956
  • Oncology 2.2k
  • Genetics 806
  • Immunology 1.3k
Replace Eduardo Olavarría with:
Eduardo Olavarría United Kingdom
Margaret V. Ragni United States
Pierre Simon Rohrlich France
Heinz A. Horst Germany
H. Grant Prentice United Kingdom
Tim Niehues Germany
Patrick A. J. Haslett United States
José Luis Díez-Martín Spain
Joseph A. DiGiuseppe United States
Carl O’Hara United States
Igor-Wolfgang Blau relative to Eduardo Olavarría United Kingdom Eduardo Olavarría's profile →
Citations per field
00.5×2×3.0×
Eduardo Olavarría · 1×
Citations per year

Countries citing papers authored by Igor-Wolfgang Blau

Since Specialization
Citations

This map shows the geographic impact of Igor-Wolfgang Blau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor-Wolfgang Blau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor-Wolfgang Blau more than expected).

Fields of papers citing papers by Igor-Wolfgang Blau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor-Wolfgang Blau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor-Wolfgang Blau. The network helps show where Igor-Wolfgang Blau may publish in the future.

Co-authors

The 25 scholars most cited alongside Igor-Wolfgang Blau, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Igor-Wolfgang Blau Line = papers co-authored together Igor-Wolfgang Blau links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 197 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Hit paper breakdown →
20091456
2
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
Hit paper breakdown →
2012689
3 2018340
4
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Hit paper breakdown →
2019316
5 2011308
6 2009258
7 2013196
8 2018195
9 2018175
10 2017162
11 2011144
12 2007136
13 2007125
14 2015113
15 2013110
16 2020109
17 2001105
18 2013102
19 201085
20 201077

About Igor-Wolfgang Blau

Igor-Wolfgang Blau is a scholar working on Hematology, Oncology, Genetics, Immunology and Public Health, Environmental and Occupational Health, having authored 197 papers that have together received 7.9k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (75 papers), Hematopoietic Stem Cell Transplantation (63 papers), Acute Myeloid Leukemia Research (60 papers), Protein Degradation and Inhibitors (36 papers), Acute Lymphoblastic Leukemia research (21 papers), Cancer Treatment and Pharmacology (20 papers), Peptidase Inhibition and Analysis (18 papers) and Immune Cell Function and Interaction (11 papers). The work is most often cited by research in Hematology (4.6k citations), Virology (956 citations), Oncology (2.2k citations), Genetics (806 citations) and Immunology (1.3k citations). Igor-Wolfgang Blau has collaborated with scholars based in Germany, France and United States. Frequent co-authors include Eckhard Thiel, Olga Blau, Susanne Ganepola, Wolf Karsten Hofmann, Thomas Schneider, Kristina Allers, Gero Hütter, Daniel R. Nowak, Jörg Hofmann and Maximilian Mossner. Their work appears in journals such as Blood, Bone Marrow Transplantation, Haematologica, Leukemia and Blood Cancer Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact